RA Eeles, AAA Olama, S Benlloch, EJ Saunders, DA Leongamornlert, M Tymrakiewicz, M Ghoussaini, C Luccarini, J Dennis, S Jugurnauth-Little, T Dadaev, DE Neal, FC Hamdy, JL Donovan, K Muir, GG Giles, G Severi, F Wiklund, H Gronberg, CA Haiman, F Schumacher, BE Henderson, L Le Marchand, S Lindstrom, P Kraft, DJ Hunter, S Gapstur, SJ Chanock, SI Berndt, D Albanes, G Andriole, J Schleutker, M Weischer, F Canzian, E Riboli, TJ Key, RC Travis, D Campa, SA Ingles, EM John, RB Hayes, PDP Pharoah, N Pashayan, K-T Khaw, JL Stanford, EA Ostrander, LB Signorello, SN Thibodeau, D Schaid, C Maier, W Vogel, AS Kibel, C Cybulski, J Lubinski, L Cannon-Albright, H Brenner, JY Park, R Kaneva, J Batra, AB Spurdle, JA Clements, MR Teixeira, E Dicks, A Lee, AM Dunning, C Baynes, D Conroy, MJ Maranian, S Ahmed, K Govindasami, M Guy, RA Wilkinson, EJ Sawyer, A Morgan, DP Dearnaley, A Horwich, RA Huddart, VS Khoo, CC Parker, NJ Van As, CJ Woodhouse, A Thompson, T Dudderidge, C Ogden, CS Cooper, A Lophatananon, A Cox, MC Southey, JL Hopper, DR English, M Aly, J Adolfsson, J Xu, SL Zheng, M Yeager, R Kaaks, WR Diver, MM Gaudet, MC Stern, R Corral, AD Joshi, A Shahabi, T Wahlfors, TLJ Tammela, A Auvinen, J Virtamo, P Klarskov, BG Nordestgaard, MA Røder, SF Nielsen, SE Bojesen, A Siddiq, LM Fitzgerald, S Kolb, EM Kwon, DM Karyadi, WJ Blot, W Zheng, Q Cai, SK McDonnell, AE Rinckleb, B Drake, G Colditz, D Wokolorczyk, RA Stephenson, C Teerlink, H Muller, D Rothenbacher, TA Sellers, H-Y Lin, C Slavov, V Mitev, F Lose, S Srinivasan, S Maia, P Paulo, E Lange, KA Cooney, AC Antoniou, D Vincent, F Bacot, DC Tessier, COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Z Kote-Jarai, DF Easton
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a custom Illumina array (iCOGS) in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium. Twenty-three new prostate cancer susceptibility loci were identified at genome-wide significance (P < 5 × 10(-8)). More than 70 prostate cancer susceptibility loci, explaining ∼30% of the familial risk for this disease, have now been identified. On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies.